-
https://www.docwirenews.com/post/checkmate-9dw-8hw-nest-and-bot-bal
Dr. Benjamin Weinberg provided his perspective on the CheckMate 9DW expanded analyses in liver cancer, as well as multiple studies in colorectal cancer, including CheckMate 8HW and NEST
Category: News
-
Ruesch Think Tank: Early Onset Cancers
Results of the Ruesch Center’s Early Onset GI Cancer Think Tank published in JNCI.
Category: News
-
Surgeon General’s alcohol warning: cancer
Dr. Benjamin Weinberg joins the Situation Room on CNN to discuss the Surgeon General’s Warming on the Link between Alcoholo and Cancer.
Category: News
-
Niche-3, CABINET, and Other GI Oncology Updates From ESMO 2024
Dr. Benjamin Weinberg shares updates from the recent ESMO meeting
Category: News
-
https://www.onclive.com/view/uncovering-the-power-of-introspection-to-drive-personalized-cancer-care
A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.
Category: News
-
Zolbetuximab’s Impact on Gastric/GEJ Adenocarcinoma
John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Category: News
-
Celebrating 15th Anniversary Ruesch Center Honors Founder
Learn more about the 15th Annual Luminary Awards
Category: News
-
ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting
John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.
Category: News
-
James Van Der Beek, Jenna Fischer and the rise of young people getting cancer
Dr. John Marshall cautions both patients and medical professionals to not brush away concerning symptoms just because someone is young in this USA Today article
Category: News
-
Zolbetuximab/Chemo Displays PFS, OS Benefits in Gastric Cancer Trials
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
Category: News